文献速递肾移植慢性肾脏病

钠-葡萄糖协同转运蛋白2抑制剂在糖尿病与非糖尿病肾移植受者中的应用

Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients.
PubMed 文献 · Kidney Int Rep · 2024-11-28

本研究为法国多中心前瞻性真实世界研究,纳入347例接受SGLT2i治疗的肾移植受者,其中65.1%为糖尿病患者。结果显示尿路感染和生殖器真菌感染发生率低,无严重不良事件;SGLT2i停药率为15.6%,低eGFR患者停药率更高;SGLT2i与蛋白尿减少相关,且在未控制高血压患者中具有降压效应。

要点

  • SGLT2i在肾移植受者中尿路感染和生殖器真菌感染发生率低,无严重不良事件。
  • 低eGFR(尤其<30 ml/min/1.73 m2)患者SGLT2i停药率最高。
  • SGLT2i与糖尿病和非糖尿病肾移植受者蛋白尿减少相关,并仅在未控制高血压患者中显示降压效应。

核心结论

  • SGLT2i在法国已用于肾移植受者,移植肾功能受损患者停药更频繁,但预期副作用不常见且非危及生命,短期降蛋白尿和降压效应值得期待。

研究设计与样本

  • 前瞻性多中心真实世界研究,纳入所有连续接受SGLT2i治疗的肾移植受者,共347例,97%使用达格列净,87%在移植后第一年后开始治疗。

主要发现

  • 226例(65.1%)为糖尿病患者,245例(70.6%)使用ACE抑制剂或ARB。
  • 尿路感染发生率为6.6%,生殖器真菌感染为0.6%,无严重不良事件。
  • 54例(15.6%)停用SGLT2i,主要原因包括移植肾功能障碍(32%)、并发感染(17%)、尿路感染(11%)和消化道症状(9%)。
  • 低eGFR患者,尤其是eGFR < 30 ml/min/1.73 m2者,SGLT2i停药发生率最高(P = 0.003)。
  • SGLT2i与糖尿病和非糖尿病肾移植受者蛋白尿减少相关,降压效应仅限于未控制高血压患者。

临床怎么用

  • 在肾移植受者中使用SGLT2i时,应关注移植肾功能,低eGFR患者停药风险较高。
  • SGLT2i可用于糖尿病和非糖尿病肾移植受者以减少蛋白尿,但降压效应仅在未控制高血压患者中显现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular prognosis in patients with chronic kidney disease (CKD), diabetes, and heart failure; and slow the decline of kidney dysfunction in patients with albuminuria. Although safety and efficacy of SGLT2i have not been investigated in kidney transplant recipients (KTRs), their marketing authorization leaves the possibility of their use in these patients in France. METHODS: This was a prospective multicenter real-life study including all consecutive KTRs treated with SGLT2i. RESULTS: We identified 347 KTRs treated with SGLT2i (97% with dapagliflozin), with an initiation of treatment most often beyond the first year after transplantation (87%). Importantly, 226 (65.1%) were diabetic and 245 (70.6%) were treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs). We found a low incidence of urinary tract infections (UTIs) (6.6%) and genital mycosis (0.6%), without any serious adverse event. Overall, SGLT2i were stopped in 54 patients (15.6%). The causes of SGLT2i discontinuations were very diverse. The main causes were graft dysfunction (32%), intercurrent infections (17%), urinary infections (11%), and digestive symptoms (9%). KTRs with a low estimated glomerular filtration rate (eGFR), especially those with eGFR < 30 ml/min per 1.73 m2, presented with the highest incidence of SGLT2i discontinuation (P = 0.003). SGLT2i were associated with a reduction in proteinuria, found in both diabetic and nondiabetic KTRs. In addition, they had an antihypertensive effect restricted to uncontrolled-hypertensive patients. CONCLUSION: SGLT2i have been used in KTRs since their authorization in France. They were discontinued more frequently in patients with impaired graft function; however, the expected side effects were infrequent and not life-threatening. The short-term antiproteinuric and antihypertensive effects are promising.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Maigret L, Basle L, Chatelet V, et al. Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients. Kidney Int Rep. 2024. PMID: 40225369. doi:10.1016/j.ekir.2024.11.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。